Related to For Some Emerging Companies, the Road to Growth Connects the U.S. and China

• LFB Licenses Thallion’s Early-Stage Candidate for Treating STEC Infections
  
• Beijing Pioneer to Provide Olink’s Duolink Product Line in China
  
• ICON and Tigermed Team Up to Facilitate Access to Chinese Patient Populations
  
• Charles River to Take Over Sino-U.S. CRO WuXi in Deal Worth $1.6B
  
• PPD Opens Vaccine Clinical Research Center in Taizhou, China
  
• Huya and China Medical City Sign Alliance to Exploit Country’s Promising Pharma Projects
  
• Icon Sets Up Additional Lab Facility in China
  
• Swedish Orphan Biovitrum and Dongbao Ink Deal for European and Chinese Markets
  
• Thermo Fisher Opens New Technology Center in Shanghai
  
• Sinovac Wins $1.8M Chinese Flu Vaccine Contract and Gets Anflu Sanctioned in Hong Kong
  
• Nycomed Takes Majority Stake in Chinese Pharma Firm Techpool Bio-Pharma
  
• Merck KGaA Buys Chinese Cell Culture Media Firm Beijing Skywing for About $18.8M
  
• SuperNova Inks Deal with KSB to Expand Diagnostic Business into China
  
• Novartis Completes $125M Acquisition of Majority Stake in Chinese Vaccines Firm
  
• EMD Millipore Opens Shanghai Biopharmaceutical Technical Center
  
• Nycomed to Market Roche’s Osteoporosis Treatment in Asia Pacific
  
• Merck Serono Opens Biomarker R&D Lab at Pharmaron’s Facility in Beijing
  
• Covidien Plans Shanghai R&D Center as Flagship of China Research Operations
  
• Rosetta Genomics to Slash 35 Jobs to Focus on MDx Commercialization in the U.S.
  
• Quintiles Deepens China Commitment with New CRO